Added to YB: 2025-09-25
Pitch date: 2025-09-23
OSE.PA [neutral]
OSE Immunotherapeutics SA
-19.76%
current return
Author Info
Lux Opes Research covers European companies. Lots of them. Sign up for the newsletter.
Company Info
OSE Immunotherapeutics SA, a clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally.
Market Cap
EUR 165.4M
Pitch Price
EUR 5.92
Price Target
N/A
Dividend
N/A
EV/EBITDA
3.41
P/E
4.93
EV/Sales
1.83
Sector
Biotechnology
Category
special_situation
OSE Immunotherapeutics (OSE France): strategy and governance collide ahead of decisive AGM
OSE.PA (quick overview): Cancer immunotherapy Tedopi in phase III (results late decade) + lusvertikimab phase IIb planned. Tense AGM pits current mgmt vs founding shareholders (25% voting rights) over strategy/financing concerns. Lusvertikimab development needs hundreds of millions €, far exceeding market cap. Partnership crucial as rivals advance.
Read full article (2 min)